
BioLife Solutions (BLFS) Stock Forecast & Price Target
BioLife Solutions (BLFS) Analyst Ratings
Bulls say
BioLife Solutions is well positioned for strong growth in the biopreservation and cell processing market, with the opening of the Aby J. Mathew Center for Biopreservation Excellence providing a showcase for its full product portfolio and potential for developing next-generation products. With a projected sales per share of $2.19, EV/Revenue multiple of 13.3x, and net cash of $2.42 per share, our 12-month target price of $32 is supported by a comparable universe analysis and may be subject to risks such as lower-than-projected growth, inability to secure additional customers, fluctuation of sales in emerging markets and foreign exchange rates, and potential dilution risk.
Bears say
BioLife Solutions is facing strong competition in the cell and gene therapy ("CGT") industry resulting in decreased sales and revenue. Their cash flow has decreased from $7.6M in 2Q25 to $6.1M in 3Q25, indicating a potential slowdown in operations and potential financial difficulty in the future. The company's reliance on a single product, CryoStor, also increases its vulnerability to market changes and potential disruptions in the bioproduction industry.
This aggregate rating is based on analysts' research of BioLife Solutions and is not a guaranteed prediction by Public.com or investment advice.
BioLife Solutions (BLFS) Analyst Forecast & Price Prediction
Start investing in BioLife Solutions (BLFS)
Order type
Buy in
Order amount
Est. shares
0 shares